Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Accumulated Expenses (2016 - 2020)

Historic Other Accumulated Expenses for Akebia Therapeutics (AKBA) over the last 5 years, with Q1 2020 value amounting to $10.3 million.

  • Akebia Therapeutics' Other Accumulated Expenses fell 3937.98% to $10.3 million in Q1 2020 from the same period last year, while for Mar 2020 it was $10.3 million, marking a year-over-year decrease of 3937.98%. This contributed to the annual value of $9.5 million for FY2019, which is 2096.51% down from last year.
  • As of Q1 2020, Akebia Therapeutics' Other Accumulated Expenses stood at $10.3 million, which was down 3937.98% from $9.5 million recorded in Q4 2019.
  • In the past 5 years, Akebia Therapeutics' Other Accumulated Expenses ranged from a high of $16.9 million in Q1 2019 and a low of $1.3 million during Q1 2016
  • Over the past 5 years, Akebia Therapeutics' median Other Accumulated Expenses value was $3.2 million (recorded in 2018), while the average stood at $5.9 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Other Accumulated Expenses surged by 42561.32% in 2019, and later crashed by 3937.98% in 2020.
  • Over the past 5 years, Akebia Therapeutics' Other Accumulated Expenses (Quarter) stood at $1.9 million in 2016, then increased by 21.74% to $2.4 million in 2017, then soared by 410.0% to $12.1 million in 2018, then decreased by 20.97% to $9.5 million in 2019, then increased by 7.48% to $10.3 million in 2020.
  • Its Other Accumulated Expenses was $10.3 million in Q1 2020, compared to $9.5 million in Q4 2019 and $8.8 million in Q3 2019.